Developing a new HIV vaccine using RNA technology
RNA-based HIV-1 chimera vaccines encoding a trimerizing host self-protein protomer linked to a viral MPER-TM segment
This study is testing a new type of HIV vaccine that uses special technology to help your immune system recognize and fight the virus, aiming to provide better protection for people living with HIV.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11062370 on NIH RePORTER |
What this research studies
This research focuses on creating a novel vaccine for HIV-1 that aims to generate broadly neutralizing antibodies (bnAbs) to combat the virus's rapid mutation. The approach involves using RNA-based technology to encapsulate specific viral protein segments, which are designed to stimulate the immune system effectively. By targeting a conserved region of the virus that is critical for its ability to infect cells, the researchers hope to enhance the immune response and provide better protection against HIV. The study will involve advanced techniques such as lipid nanoparticles to deliver the vaccine components safely and effectively.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for HIV infection or those living with HIV who are seeking new treatment options.
Not a fit: Patients who are not at risk for HIV or those who are already effectively managing their HIV with existing treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking vaccine that provides long-lasting immunity against HIV-1.
How similar studies have performed: While the approach is innovative, previous research has shown promise in developing vaccines targeting similar viral components, indicating potential for success.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Reinherz, Ellis L — Dana-Farber Cancer Inst
- Study coordinator: Reinherz, Ellis L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.